Friday, Nov 13, 1987
South San Francisco, Calif. -- November 13, 1987 --Genentech, Inc. announced today that Genentech Canada, its joint venture with Boehringer Ingelheim (Canada) Ltd., its joint venture with Boehringer Ingelheim (Canada) Ltd., has received approval to market tissue plasminogen activator (t-PA) in Canada. T-PA, which will be marketed in North America under the trademark Activase® has been approved for dissolving blood clots that cause heart attacks.
"For Canadians, Activase is considered an important breakthrough in critical care therapy, since heart attacks are a major killer in this country," said Dr. Jack Hirsh, professor and chairman of the Department of Medicine, McMaster University, Hamilton, Ontario.
Statistics Canada, the government information service, estimates that the 165,000 Canadians see a physician with symptoms of heart attack each year, with over 40,000 attacks being fatal.T-PA has been approved in ten countries to date, including the United States, West Germany, Austria, France, Brazil, New Zealand, Luxembourg, the Philippines and South Korea. Genentech will receive royalties on product sales in countries outside North America. Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #